{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:01:17Z","timestamp":1793970077906,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bioorg.2025.108880","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:33:13Z","timestamp":1755822793000},"page":"108880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of liver-targeting phosphoric acid thyroid hormone receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"164","author":[{"given":"Chao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiwu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108880_bb0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.108880_bb0010","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1126\/science.aay0542","article-title":"An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis","volume":"367","author":"Zhao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.108880_bb0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease-a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2025.108880_bb0020","article-title":"Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"3","author":"Younossi","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.bioorg.2025.108880_bb0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2025.108880_bb0030","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/hep.31857","article-title":"Functional characterization of organoids derived from irreversibly damaged liver of patients with MASH","volume":"74","author":"McCarron","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.108880_bb0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.108880_bb0040","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2025.108880_bb0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2025.108880_bb0050","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108880_bb0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108880_bb0060","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemai: roles of thyroid hormones, metabolites and agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.bioorg.2025.108880_bb0065","first-page":"184","article-title":"Thyroid hormone receptors: multiple forms, multiple possibilities","volume":"14","author":"Lazar","year":"1993","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bioorg.2025.108880_bb0070","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1152\/physrev.2001.81.3.1097","article-title":"Physiological and molecular basis of thyroid hormone action","volume":"81","author":"Yen","year":"2001","journal-title":"Physiol. Rev."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108880_bb0075","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJM199409293311306","article-title":"The molecular basis of thyroid hormone action","volume":"331","author":"Brent","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108880_bb0080","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1210\/en.2003-0973","article-title":"Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3\u2032-triiodo-Lthyronine","volume":"145","author":"Grover","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.bioorg.2025.108880_bb0085","doi-asserted-by":"crossref","first-page":"10297","DOI":"10.1073\/pnas.0504379102","article-title":"Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice","volume":"102","author":"Johansson","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.108880_bb0090","doi-asserted-by":"crossref","first-page":"14840","DOI":"10.1021\/acs.jmedchem.4c01029","article-title":"Discovery and preclinical profile of ALG-055009, a potent and selective thyroid hormone receptor beta (THR-\u03b2) agonist for the treatment of MASH","volume":"67","author":"Vandyck","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108880_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1515\/jbcpp-2024-0140","article-title":"Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials","volume":"36","author":"Hazem","year":"2025","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108880_bb0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jhep.2024.08.008","article-title":"Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids","volume":"82","author":"Zhang","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2025.108880_bb0105","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"82","author":"Vlad","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2025.108880_bb0110","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.1021\/jm800824d","article-title":"Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs","volume":"51","author":"Boyer","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108880_bb0115","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"Kelly","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108880_bb0120","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108880_bb0125","doi-asserted-by":"crossref","first-page":"15490","DOI":"10.1073\/pnas.0702759104","article-title":"Targeting thyroid hormone receptor-Beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index","volume":"104","author":"Erion","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.108880_bb0130","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1124\/dmd.108.021642","article-title":"Preclinical pharmacokinetics of a Hepdirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist","volume":"36","author":"Fujitaki","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bioorg.2025.108880_bb0135","series-title":"American Association for the Study of Liver Disease, San Francisco, USA, November 9-13","author":"Lombda","year":"2018"},{"key":"10.1016\/j.bioorg.2025.108880_bb0140","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/j.cell.2024.05.009","article-title":"Resmetirom for treatment of MASH","volume":"187","author":"Silvia","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108880_bb0145","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108880_bb0150","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/acs.jmedchem.2c01669","article-title":"Discovery of highly potent and selective thyroid hormone receptor \u03b2 agonists for the treatment of nonalcoholic steatohepatitis","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:31:22Z","timestamp":1762223482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825007606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"alternative-id":["S0045206825007606"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108880","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of liver-targeting phosphoric acid thyroid hormone receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108880"}}